Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Drug resistance significantly contributes to mortality in epithelial ovarian carcinoma (EOC) patients.
• Effective strategies to overcome chemoresistance in EOC remain limited.
• The role of microRNA-9 (miR-9) in regulating paclitaxel sensitivity in EOC requires elucidation.

Purpose of the Study:

• To investigate the role of miR-9 in the regulation of paclitaxel sensitivity in epithelial ovarian carcinoma (EOC).
• To identify the underlying mechanisms by which miR-9 influences chemoresistance.
• To explore the potential of targeting miR-9 for therapeutic interventions in EOC.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) to assess miR-9 expression in EOC cells and tissues.
• Dual-luciferase reporter assays and Western blotting to validate miR-9 targets.
• Methylation studies, RNA interference (RNAi), and cytotoxicity assays to determine miR-9's mechanism in paclitaxel sensitivity.

Main Results:

• miR-9 expression was found to be downregulated in paclitaxel-resistant EOC.
• Lower miR-9 levels, advanced stage, and suboptimal surgery correlated with shorter survival times in EOC patients.
• CCNG1 was identified as a direct target of miR-9, mediating paclitaxel resistance.
• Hypermethylation of miR-9 genes decreased its expression, while demethylation restored expression and improved sensitivity.
• Paclitaxel exposure induced methylation-associated miR-9 deregulation in EOC cells.

Conclusions:

• Downregulation of miR-9, associated with gene methylation, is a key mechanism driving paclitaxel resistance in EOC via CCNG1.
• Restoring miR-9 expression can enhance paclitaxel sensitivity in chemoresistant EOC cells.
• These findings suggest miR-9 as a potential therapeutic target to overcome paclitaxel resistance in EOC.